Chronic schizophrenia
Conditions
Interventions
Group A:A nasal spray of oxytocin 24 IU was given before breakfast (each nostril received three sprays) and the same dose of saline was given before dinner
for two consecutive weeks.
Group B:Saline 24 IU nasal spray was given before breakfast (each nostril received three sprays) and the same dose of oxytocin was given before dinner
Group C:A nasal spray of oxytocin 24 IU was given before breakfast and before dinner (each nostril received three sprays)
Control Group:Saline 24 IU nasal spray was given before breakfast and before dinner (each nostril received three sprays)
for a fortnight.
Sponsors
Huzhou Third People's Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: a. meet the DSM-5 diagnostic criteria for schizophrenia, the disease is in a stable phase, and the PANSS score is <60, with the following item scores =4 (e.g., P4, P6, P7, G2, G4, G8, and G14); b. be 18-45 years old and male; c. the subject is currently taking second-generation antipsychotics (=2) at a dose not exceeding the maximum dose specified in the instructions, and the The dose and frequency of administration were basically stable in the last 2 weeks; d. Literacy above junior high school; e. Han Chinese, right-handed; f. Able to understand the experimental instructions; g. Subjects or their guardians fully understood the purpose and requirements of this trial, voluntarily participated in the trial and signed a written informed consent form.
Exclusion criteria
Exclusion criteria: a. Patients who meet DSM-5 diagnostic criteria for other psychiatric disorders; b. Those with organic brain and serious physical illnesses and taking prescription or over-the-counter medications; c. Those with a history of coma from craniocerebral injuries; d. Those with previous seizures or a family history of epilepsy; e. Those with current infections, trauma, and concomitant immune disorders, or other medical illnesses; f. Those with a history of drug or substance abuse in the last 1 year or with a urine drug screen that is positive urine drug screen (except benzodiazepines); g. Smoking within the last 3 months, with an average of >10 cigarettes per day; h. Alcohol consumption within the last 6 months, with an average weekly alcohol intake of more than 14 units (1 unit is equal to 285 ml of beer or 25 ml of spirits or 150 ml of wine); i. Significant history of blood loss or =200 ml of blood loss in the last 3 months; j. Possible allergic reaction to any of the components of the drug; k. Possible hypersensitivity to any of the components of the drug; l. Positive urine drug screen; m. Positive urine drug screen; n. Positive urine drug screen. Allergy; k. Admission to or participation in other clinical trials within the last 3 months; l. Significant nasal mucosa and septum abnormalities; m. Contraindications to MRI; n. Mental retardation; o. Wechsler's Adult Intelligence Scale score of less than 86.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale;CHINESE VERSION OF BRIEF NEUROCOGNITIVE TEST BATTERY;Chinese facial affective picture system;Metaphorical tasks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Oxytocin (OXT) quantitative assay; | — |
Countries
China
Contacts
Public ContactWang Hong
Huzhou Third People's Hospital
Outcome results
None listed